INTRODUCTION: A case of cefepime-induced nonconvulsive status epilepticus in a 15-year-old child with end stage renal disease on hemodialysis is reported. Clinical symptoms and EEG dramatically improved 48 h after discontinuation of cefepime. METHODS: Twenty-five cases of nonconvulsive status epilepticus associated with cefepime that have been reported in the literature are reviewed. RESULTS: The average age was 60 years [15-86], our patient is the second pediatric patient reported, and 56% of cases occurred in women. The cefepime dosage was adjusted to the renal function in 5 cases. All except 1 patient have impaired renal function (CRF: 17 cases, ARF: 7 cases). The symptoms start 1-15 days after starting cefepime, mean 6 days. The outcome was good after discontinuation of cefepime therapy and anticonvulsant treatment, but lethal outcome was also reported in 2 cases. One fatality was related to status epilepticus. CONCLUSION: The clinicians' awareness must be increased about cefepime-induced nonconvulsive status epilepticus.
INTRODUCTION: A case of cefepime-induced nonconvulsive status epilepticus in a 15-year-old child with end stage renal disease on hemodialysis is reported. Clinical symptoms and EEG dramatically improved 48 h after discontinuation of cefepime. METHODS: Twenty-five cases of nonconvulsive status epilepticus associated with cefepime that have been reported in the literature are reviewed. RESULTS: The average age was 60 years [15-86], our patient is the second pediatric patient reported, and 56% of cases occurred in women. The cefepime dosage was adjusted to the renal function in 5 cases. All except 1 patient have impaired renal function (CRF: 17 cases, ARF: 7 cases). The symptoms start 1-15 days after starting cefepime, mean 6 days. The outcome was good after discontinuation of cefepime therapy and anticonvulsant treatment, but lethal outcome was also reported in 2 cases. One fatality was related to status epilepticus. CONCLUSION: The clinicians' awareness must be increased about cefepime-induced nonconvulsive status epilepticus.
Authors: D Chatellier; M Jourdain; J Mangalaboyi; F Ader; C Chopin; P Derambure; F Fourrier Journal: Intensive Care Med Date: 2001-12-04 Impact factor: 17.440
Authors: J E Martínez-Rodríguez; F J Barriga; J Santamaria; A Iranzo; J A Pareja; M Revilla; C R dela Rosa Journal: Am J Med Date: 2001-08 Impact factor: 4.965
Authors: N Ferrara; P Abete; M Giordano; P Ferrara; V Carnovale; D Leosco; F Beneduce; T Ciarambino; M Varricchio; F Rengo Journal: Clin Nephrol Date: 2003-05 Impact factor: 0.975
Authors: Aziza K Chedrawi; Salam I Gharaybeh; Saed A Al-Ghwery; Sulaiman A Al-Mohaimeed; Saad A Alshahwan Journal: Pediatr Neurol Date: 2004-02 Impact factor: 3.372
Authors: F Anzellotti; L Ricciardi; D Monaco; F Ciccocioppo; I Borrelli; H Zhuzhuni; M Onofrj Journal: Neurol Sci Date: 2011-07-01 Impact factor: 3.307